Podcast

Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer

Author(s):

OncLive Staff

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
Seth Wander, MD, PhD
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Oleg Gluz, MD
Cynthia X. Ma, MD, PhD
Ann H. Partridge, MD, MPH
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Related Content
Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California, as well as a health sciences clinical professor at the University of California, Los Angeles
October 8th 2024

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Breast cancer Image Credit: © Axel Kock - stock.adobe.com
October 7th 2024

Neoadjuvant Pertuzumab Biosimilar Plus Trastuzumab/Docetaxel Meets pCR End Point in HER2+ Breast Cancer

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD
October 2nd 2024

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California. She is also a health sciences clinical professor at the University of California, Los Angeles.
October 5th 2024

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology